Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma

NCT02730923 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT02730923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02730923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Lead sponsor
Centre Leon Berard
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 30, 2016
Completion date
December 31, 2024
Enrollment
72 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial carcinoma, hormone receptor positive tumor, metastatic carcinoma